Menu
Search
|

Menu

Close
X

Insmed Inc INSM.OQ (NASDAQ Stock Exchange Global Select Market)

21.41 USD
-0.12 (-0.56%)
As of 4:46 PM BST
Previous Close 21.53
Open 21.46
Volume 74,207
3m Avg Volume 320,198
Today’s High 21.65
Today’s Low 21.18
52 Week High 33.09
52 Week Low 11.31
Shares Outstanding (mil) 76.50
Market Capitalization (mil) 2,392.91
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.89 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY19
22
FY18
10
FY17
0
FY16
0
EPS (USD)
FY19
-0.956
FY18
-4.216
FY17
-2.865
FY16
-2.848
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
--
7.92
Price to Book (MRQ)
vs sector
23.38
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
66.14
14.56
LT Debt to Equity (MRQ)
vs sector
66.14
10.21
Return on Investment (TTM)
vs sector
-92.57
14.49
Return on Equity (TTM)
vs sector
-112.72
15.79

EXECUTIVE LEADERSHIP

William Lewis
Chairman of the Board, President, Chief Executive Officer, Since 2018
Salary: $610,000.00
Bonus: --
John Goll
Chief Accounting Officer, Since 2019
Salary: --
Bonus: --
John Soriano
Chief Compliance Officer, Since 2019
Salary: --
Bonus: --
Roger Adsett
Chief Commercial Officer, Since 2016
Salary: $458,280.00
Bonus: --
Christine Pellizzari
Chief Legal Officer, Since 2018
Salary: $436,110.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10 Finderne Ave Bldg 10
BRIDGEWATER   NJ   08807-3365

Phone: +1908.9779900

Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

SPONSORED STORIES